[{"id":"08acf605-b07c-43c2-9ea5-49c6a40c4eda","acronym":"FPA150-001","url":"https://clinicaltrials.gov/study/NCT03514121","created_at":"2021-11-15T18:58:34.414Z","updated_at":"2024-07-02T16:36:18.695Z","phase":"Phase 1a/1b","brief_title":"FPA150 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03514121 - FPA150-001","lead_sponsor":"Five Prime Therapeutics, Inc.","biomarkers":" VTCN1","pipe":" | ","alterations":" VTCN1 underexpression","tags":["VTCN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VTCN1 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • alsevalimab (FPA150)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 03/27/2018","start_date":" 03/27/2018","primary_txt":" Primary completion: 05/10/2021","primary_completion_date":" 05/10/2021","study_txt":" Completion: 05/10/2021","study_completion_date":" 05/10/2021","last_update_posted":"2022-01-11"}]